These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 34291512)

  • 1. Hypophosphataemia Following Ferric Carboxymaltose Infusion.
    McGrath KH; Khoo PWR
    J Paediatr Child Health; 2021 Sep; 57(9):1546. PubMed ID: 34291512
    [No Abstract]   [Full Text] [Related]  

  • 2. Hypophosphataemia following ferric carboxymaltose and ferric derisomaltose: case closed, but questions remain.
    Chauhan A; Lucas S; Garg M
    Gut; 2024 May; 73(6):1039. PubMed ID: 37193585
    [No Abstract]   [Full Text] [Related]  

  • 3. Refractory hypophosphatemia following ferric carboxymaltose administration.
    Efe O; García JDC; Mount DB; Sheridan AM
    CEN Case Rep; 2021 Nov; 10(4):473-475. PubMed ID: 33715107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypophosphataemia after ferric carboxymaltose is unrelated to symptoms, intestinal inflammation or vitamin D status.
    Fang W; Kenny R; Rizvi QU; McMahon LP; Garg M
    BMC Gastroenterol; 2020 Jun; 20(1):183. PubMed ID: 32522150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Dose Ferric Carboxymaltose in Patients With HFrEF Induces Significant Hypophosphatemia.
    Stöhr R; Sandstede L; Heine GH; Marx N; Brandenburg V
    J Am Coll Cardiol; 2018 May; 71(19):2270-2271. PubMed ID: 29747838
    [No Abstract]   [Full Text] [Related]  

  • 6. Ferric carboxymaltose (Ferinject®) associated hypophosphataemia: case report illustrating the need for increased awareness to minimise incidence and risk.
    Fisher S; Jonker L
    Acute Med; 2020; 19(2):102-105. PubMed ID: 32840261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypophosphatemia in children treated with ferric carboxymaltose.
    Posod A; Schaefer B; Mueller T; Zoller H; Kiechl-Kohlendorfer U
    Acta Paediatr; 2020 Jul; 109(7):1491-1492. PubMed ID: 31955454
    [No Abstract]   [Full Text] [Related]  

  • 8. Symptomatic hypophosphataemic osteomalacia secondary to the treatment with iron carboxymaltose detected in bone scintigraphy.
    Sangrós Sahún MJ; Goñi Gironés E; Camarero Salazar A; Estébanez Estébanez C; Lozano Martínez ME
    Rev Esp Med Nucl Imagen Mol; 2016; 35(6):391-393. PubMed ID: 27246291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphorus levels in children treated with intravenous ferric carboxymaltose.
    Kirk SE; Scheurer ME; Bernhardt MB; Mahoney DH; Powers JM
    Am J Hematol; 2021 Jun; 96(6):E215-E218. PubMed ID: 33735470
    [No Abstract]   [Full Text] [Related]  

  • 10. Severe hypophosphatemia after intravenous administration of iron carboxymaltose in a stable renal transplant recipient.
    Mani LY; Nseir G; Venetz JP; Pascual M
    Transplantation; 2010 Oct; 90(7):804-5. PubMed ID: 20881582
    [No Abstract]   [Full Text] [Related]  

  • 11. What is wrong in doing good?
    Zoller H; Wagner S; Schaefer B
    Br J Haematol; 2023 Sep; 202(6):1089-1090. PubMed ID: 37528542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of hypophosphatemia in patients with inflammatory bowel disease treated with ferric carboxymaltose or iron isomaltoside.
    Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
    Aliment Pharmacol Ther; 2019 Aug; 50(4):397-406. PubMed ID: 31264261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ferric carboxymaltose treatment for iron deficiency anemia in children with inflammatory bowel disease: Efficacy and risk of hypophosphatemia.
    Cococcioni L; Pensabene L; El-Khouly S; Chadokufa S; McCartney S; Saliakellis E; Kiparissi F; Borrelli O
    Dig Liver Dis; 2021 Jul; 53(7):830-834. PubMed ID: 33775573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ferric carboxymaltose-induced hypophosphataemia after kidney transplantation.
    Sari V; Atiqi R; Hoorn EJ; Heijboer AC; van Gelder T; Hesselink DA
    Neth J Med; 2017 Mar; 75(2):65-73. PubMed ID: 28276325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypophosphatemia Is Common After Intravenous Ferric Carboxymaltose Infusion Among Patients With Symptomatic Heart Failure With Reduced Ejection Fraction.
    Dashwood A; Vale C; Laher S; Chui F; Hay K; Wong YW
    J Clin Pharmacol; 2021 Apr; 61(4):515-521. PubMed ID: 33051909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe hypophosphatemia secondary to chronic treatment with endovenous ferric carboxymaltose.
    González Hidalgo V; Morán López JM
    Endocrinol Diabetes Nutr (Engl Ed); 2022 Oct; 69(8):646-647. PubMed ID: 36335081
    [No Abstract]   [Full Text] [Related]  

  • 17. Severe FGF23-based hypophosphataemic osteomalacia due to ferric carboxymaltose administration.
    Klein K; Asaad S; Econs M; Rubin JE
    BMJ Case Rep; 2018 Jan; 2018():. PubMed ID: 29298794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case report: A rare cause of severe hypophosphatemia.
    Román-Gimeno S; Ortez-Toro JJ; Peteiro-Miranda CM; Sanz-Martín B; Urdaniz-Borque R
    Ann Endocrinol (Paris); 2020 Jun; 81(2-3):125-126. PubMed ID: 32409006
    [No Abstract]   [Full Text] [Related]  

  • 19. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside-a systematic review and meta-analysis.
    Schaefer B; Tobiasch M; Viveiros A; Tilg H; Kennedy NA; Wolf M; Zoller H
    Br J Clin Pharmacol; 2021 May; 87(5):2256-2273. PubMed ID: 33188534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose-the randomized controlled HOMe aFers study.
    Emrich IE; Lizzi F; Siegel JD; Seiler-Mussler S; Ukena C; Kaddu-Mulindwa D; D'Amelio R; Wagenpfeil S; Brandenburg VM; Böhm M; Fliser D; Heine GH
    BMC Med; 2020 Jul; 18(1):178. PubMed ID: 32654663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.